Novum Selects OmniComm as Strategic EDC Partner
FORT LAUDERDALE, Fla., Oct. 19, 2017 (GLOBE NEWSWIRE)-Novum Pharmaceutical Research Services, a U.S. CRO, has selected TrialMaster electronic data capture (EDC) technology from OmniComm Systems, Inc., (OTCQX:OMCM), a global provider of clinical data management technology. Novum will use TrialMaster to conduct more than 200 research studies annually across virtually all dosage forms and indications. Founded in 1972, the Pittsburgh-based CRO conducts Phase I to Phase IV complex generic and new drug clinical trials.
“Novum conducts a high volume of diverse, complex, and technically challenging early- and late-phase clinical trials,” said Christopher H. Chamberlain, CEO of Novum. “In order for us to provide high-quality deliverables under tight timelines, we selected OmniComm’s technology due to TrialMaster’s flexibility, ease-of-use and broad capabilities.”
Compelling TrialMaster features include intuitive user interface, real-time edit checks, real-time reporting, and the ability to customize data exports. Specific features for emphasis for TrialMaster’s selection include:
Ability to build studies more efficiently and effectively.
Adeptness in query management workflow.
Intuitive interface for all key user groups.
Dynamic monitoring and centralized source review.
Ability to export SDTM datasets directly from TrialMaster using Custom Data Export
UtilityTM.
Broad range of pre-built, real-time standard reports and real-time ad-hoc reporting.
Flexible and very user-friendly eLearning modules.
Professional and experienced regional-based services and support organization.
”We are delighted to have been selected by Novum to support its demanding clinical research needs,” said Stephen Johnson, president and CEO of OmniComm. “Novum’s requirement for a flexible, intuitive solution that expedites the company’s clinical trial timelines typifies the demands we see across the industry. It’s not enough to utilize EDC to drive efficiency anymore; the EDC solutions available today need to do more and drive innovation into the process. It is this basic principle that has catalyzed our growth over the last several years, and we are happy to be working with such a prestigious organization that is so focused on finding better ways to bring life-saving drugs and devices to the market.”
Supporting Information
Gustave Roussy Signs Five-Year Commitment for OmniComm’s TrialMaster® EDC to Support Cancer Research
OmniComm Systems Signs Five-Year, $8.4 Million Contract With Top-Tier Research Hospital
Five-Year Agreement with Top 5 US Medical Research University
European Hospital Leverages OmniComm Systems’TrialMaster® EDC To Integrate
Electronic Health Records
TrialMaster
About OmniComm Systems, Inc.
OmniComm Systems, Inc. is a leading strategic software solutions provider to the life sciences industry.
OmniComm is dedicated to helping the world’s pharmaceutical, biotechnology, contract research organizations, diagnostic and device firms, and academic medical centers maximize the value of their clinical research investments. Through the use of innovative and progressive technologies, these organizations drive efficiency in clinical development, better manage their risks, ensure regulatory compliance, and manage their clinical operations performance. With an extensive global experience from more than 5,000 clinical trials, OmniComm provides comprehensive solutions for clinical research. Please visit www.omnicomm.com for more information.
About Novum Pharmaceutical Research Services
Novum Pharmaceutical Research Services is a U.S. contract research organization (CRO) that provides Phase I through Phase IV clinical research, data management, statistical and reporting services to the pharmaceutical and related industries. The 45-year-old CRO, operates early-phase research facilities in three U.S. locations. Novum's Clinical Trial Management group conducts Phase II through Phase IV clinical endpoint studies requiring large patient numbers across numerous therapeutic areas. Please visit www.novumprs.com for more corporate information.
Trademarks
OmniComm, TrialMaster, TrialOne, and Promasys are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.
Contact Info
Kuno van der Post OmniComm Systems, Inc. +1.954.473.1254 KvanderPost@omnicomm.com
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
